Oncotelic Therapeutics Inc
OTC:OTLC
Oncotelic Therapeutics Inc
OTC:OTLC
Price:
0.0382 USD
-1.55%
Market Closed
Updated:
May 11, 2024
Oncotelic Therapeutics Inc
Research & Development
|
Oncotelic Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Oncotelic Therapeutics Inc
OTC:OTLC
|
Research & Development
-$61.1k
|
CAGR 3-Years
76%
|
CAGR 5-Years
37%
|
CAGR 10-Years
34%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Oncotelic Therapeutics Inc's Research & Development?
Research & Development
-61.1k
USD
-61.1k
USD
Based on the financial report for Dec 31, 2023, Oncotelic Therapeutics Inc's Research & Development amounts to -61.1k USD.
What is Oncotelic Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
34%
34%
Over the last year, the Research & Development growth was 92%. The average annual Research & Development growth rates for Oncotelic Therapeutics Inc have been 76% over the past three years , 37% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet
